Oligonucleotide-based therapy for FTD/ALS caused by the C9orf72 repeat expansion: A perspective

Journal of Nucleic Acids

Volumn 2013, Issue , 2013, Pages

  Fernandes, Stephanie A ^a   Douglas, Andrew G L ^a,b   Varela, Miguel A ^a   Wood, Matthew J A ^a   Aoki, Yoshitsugu ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; DNA; LITHIUM CARBONATE; LOCKED NUCLEIC ACID; MEMANTINE; MESSENGER RNA; MINOCYCLINE; MORPHOLINO OLIGONUCLEOTIDE; RIBONUCLEASE H; RILUZOLE; RNA; SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; C9ORF72 GENE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENE; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; OPEN READING FRAME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; RNA SPLICING; STEM CELL TRANSPLANTATION;

EID: 84890059739     PISSN: 20900201     EISSN: 2090021X     Source Type: Journal    
DOI: 10.1155/2013/208245     Document Type: Review

References (102)

1. Mulder D. W., Clinical limits of amyotrophic lateral sclerosis. Advances in Neurology 1982 36 15 22 2-s2.0-0020391968
2. Lashley T., Hardy J., Isaacs A. M., Previews RANTing about C9orf72. Neuron 2013 77 597 598
3. Pasinelli P., Brown R. H., Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nature Reviews Neuroscience 2006 7 9 710 723 2-s2.0-33747605320 10.1038/nrn1971 (Pubitemid 44267495)
4. Harvey R. J., Skelton-Robinson M., Rossor M. N., The prevalence and causes of dementia in people under the age of 65 years. Journal of Neurology, Neurosurgery and Psychiatry 2003 74 9 1206 1209 2-s2.0-0141740739 10.1136/jnnp.74.9.1206 (Pubitemid 37152242)
5. Graff-Radford N. R., Woodruff B. K., Frontotemporal dementia. Seminars in Neurology 2007 27 1 48 57 2-s2.0-33846934718 10.1055/s-2006-956755 (Pubitemid 46239039)
6. van Blitterswijk M., DeJesus-Hernandez M., Rademakers R., How do C9orf72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Current Opinion in Neurology 2012 25 689 700
7. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., Nicholson A. M., Finch N. A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.-Y. R., Karydas A., Seeley W. W., Josephs K. A., Coppola G., Geschwind D. H., Wszolek Z. K., Feldman H., Knopman D. S., Petersen R. C., Miller B. L., Dickson D. W., Boylan K. B., Graff-Radford N. R., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 2011 72 2 245 256 2-s2.0-80054832080 10.1016/j.neuron.2011.09.011
8. Renton A. E., Majounie E., Waite A., Simón-Sánchez J., Rollinson S., Gibbs J. R., Schymick J. C., Laaksovirta H., van Swieten J. C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A. M., Kaganovich A., Scholz S. W., Duckworth J., Ding J., Harmer D. W., Hernandez D. G., Johnson J. O., Mok K., Ryten M., Trabzuni D., Guerreiro R. J., Orrell R. W., Neal J., Murray A., Pearson J., Jansen I. E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J. B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M. A., Peuralinna T., Jansson L., Isoviita V.-M., Kaivorinne A.-L., Hölttä-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chiò A., Restagno G., Borghero G., Sabatelli M., Heckerman D., Rogaeva E., Zinman L., Rothstein J. D., Sendtner M., Drepper C., Eichler E. E., Alkan C., Abdullaev Z., Pack S. D., Dutra A., Pak E., Hardy J., Singleton A., Williams N. M., Heutink P., Pickering-Brown S., Morris H. R., Tienari P. J., Traynor B. J., A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 72 2 257 268 2-s2.0-80054837386 10.1016/j.neuron.2011.09.010
9. Giordana M. T., Ferrero P., Grifoni S., Pellerino A., Naldi A., Montuschi A., Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. Neurological Sciences 2011 32 1 9 16 2-s2.0-79551574587 10.1007/s10072-010-0439-6
10. Lomen-Hoerth C., Murphy J., Langmore S., Kramer J. H., Olney R. K., Miller B., Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003 60 7 1094 1097 2-s2.0-0037426388 (Pubitemid 36418766)
11. Lomen-Hoerth C., Anderson T., Miller B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002 59 7 1077 1079 2-s2.0-0037044240
12. Phukan J., Pender N. P., Hardiman O., Cognitive impairment in amyotrophic lateral sclerosis. The Lancet Neurology 2007 6 11 994 1003 2-s2.0-35248823549 10.1016/S1474-4422(07)70265-X (Pubitemid 47562321)
13. Ringholz G. M., Appel S. H., Bradshaw M., Cooke N. A., Mosnik D. M., Schulz P. E., Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005 65 4 586 590 2-s2.0-23844511513 10.1212/01.wnl.0000172911.39167. b6 (Pubitemid 41170719)
14. Burrell J. R., Kiernan M. C., Vucic S., Hodges J. R., Motor neuron dysfunction in frontotemporal dementia. Brain 2011 134 9 2582 2594 2-s2.0-80052924149 10.1093/brain/awr195
15. Neumann M., Sampathu D. M., Kwong L. K., Truax A. C., Micsenyi M. C., Chou T. T., Bruce J., Schuck T., Grossman M., Clark C. M., McCluskey L. F., Miller B. L., Masliah E., Mackenzie I. R., Feldman H., Feiden W., Kretzschmar H. A., Trojanowski J. Q., Lee V. M.-Y., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006 314 5796 130 133 2-s2.0-33749632259 10.1126/science.1134108 (Pubitemid 44547757)
16. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J. P., Deng H.-X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S. M., Berger R., Tanzi R. E., Halperin J. J., Herzfeldt B., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993 362 6415 59 62 2-s2.0-0027401203 10.1038/362059a0 (Pubitemid 23087289)
17. Laaksovirta H., Peuralinna T., Schymick J. C., Scholz S. W., Lai S.-L., Myllykangas L., Sulkava R., Jansson L., Hernandez D. G., Gibbs J. R., Nalls M. A., Heckerman D., Tienari P. J., Traynor B. J., Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. The Lancet Neurology 2010 9 10 978 985 2-s2.0-77956876046 10.1016/S1474-4422(10)70184-8
18. Morita M., Al-Chalabi A., Andersen P. M., Hosler B., Sapp P., Englund E., Mitchell J. E., Habgood J. J., De Belleroche J., Xi J., Jongjaroenprasert W., Horvitz H. R., Gunnarsson L.-G., Brown R. H. Jr., A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006 66 6 839 844 2-s2.0-33645062075 10.1212/01.wnl.0000200048.53766.b4 (Pubitemid 43739757)
19. Mok K., Traynor B. J., Schymick J., Tienari P. J., Laaksovirta H., Peuralinna T., Myllykangas L., Chiò A., Shatunov A., Boeve B. F., Boxer A. L., DeJesus-Hernandez M., Mackenzie I. R., Waite A., Williams N., Morris H. R., Simón-Sánchez J., van Swieten J. C., Heutink P., Restagno G., Mora G., Morrison K. E., Shaw P. J., Rollinson P. S., Al-Chalabi A., Rademakers R., Pickering-Brown S., Orrell R. W., Nalls M. A., Hardy J., The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging 2012 33 1 e3 e8 2-s2.0-81355146748 10.1016/j.neurobiolaging.2011.08.005
20. Gijselinck I., van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., Engelborghs S., Sieben A., De Jonghe P., Vandenberghe R., Santens P., De Bleecker J., Maes G., Bäumer V., Dillen L., Joris G., Cuijt I., Corsmit E., Elinck E., Van Dongen J., Vermeulen S., Van den Broeck M., Vaerenberg C., Mattheijssens M., Peeters K., Robberecht W., Cras P., Martin J.-J., De Deyn P. P., Cruts M., Van Broeckhoven C., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. The Lancet Neurology 2012 11 1 54 65 2-s2.0-83555166183 10.1016/S1474-4422(11)70261-7
21. Chiò A., Borghero G., Restagno G., Mora G., Drepper C., Traynor B. J., Sendtner M., Brunetti M., Ossola I., Calvo A., Pugliatti M., Sotgiu M. A., Murru M. R., Marrosu M. G., Marrosu F., Marinou K., Mandrioli J., Sola P., Caponnetto C., Mancardi G., Mandich P., La Bella V., Spataro R., Conte A., Monsurrò M. R., Tedeschi G., Pisano F., Bartolomei I., Salvi F., Lauria Pinter G., Simone I., Logroscino G., Gambardella A., Quattrone A., Lunetta C., Volanti P., Zollino M., Penco S., Battistini S., Renton A. E., Majounie E., Abramzon Y., Conforti F. L., Giannini F., Corbo M., Sabatelli M., Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72. Brain 2012 135 3 784 793 2-s2.0-84857522741 10.1093/brain/awr366
22. Cooper-Knock J., Hewitt C., Highley J. R., Brockington A., Milano A., Man S., Martindale J., Hartley J., Walsh T., Gelsthorpe C., Baxter L., Forster G., Fox M., Bury J., Mok K., McDermott C. J., Traynor B. J., Kirby J., Wharton S. B., Ince P. G., Hardy J., Shaw P. J., Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9orf72. Brain 2012 135 3 751 764 2-s2.0-84857054634 10.1093/brain/awr365
23. Majounie E., Renton A. E., Mok K., Dopper E. G. P., Waite A., Rollinson S., Chiò A., Restagno G., Nicolaou N., Simon-Sanchez J., van Swieten J. C., Abramzon Y., Johnson J. O., Sendtner M., Pamphlett R., Orrell R. W., Mead S., Sidle K. C., Houlden H., Rohrer J. D., Morrison K. E., Pall H., Talbot K., Ansorge O., Hernandez D. G., Arepalli S., Sabatelli M., Mora G., Corbo M., Giannini F., Calvo A., Englund E., Borghero G., Floris G. L., Remes A. M., Laaksovirta H., McCluskey L., Trojanowski J. Q., Van Deerlin V. M., Schellenberg G. D., Nalls M. A., Drory V. E., Lu C.-S., Yeh T.-H., Ishiura H., Takahashi Y., Tsuji S., Le Ber I., Brice A., Drepper C., Williams N., Kirby J., Shaw P., Hardy J., Tienari P. J., Heutink P., Morris H. R., Pickering-Brown S., Traynor B. J., Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. The Lancet Neurology 2012 11 4 323 330 2-s2.0-84858619539 10.1016/S1474-4422(12)70043-1
24. Millecamps S., Boillée S., le Ber I., Phenotype difference between ALS patients with expanded repeats in C9orf72 and patients with mutations in other ALS-related genes. Journal of Medical Genetics 2012 49 258 263
25. Snowden J. S., Rollinson S., Thompson J. C., Harris J. M., Stopford C. L., Richardson A. M. T., Jones M., Gerhard A., Davidson Y. S., Robinson A., Gibbons L., Hu Q., DuPlessis D., Neary D., Mann D. M. A., Pickering-Brown S. M., Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9orf72 mutations. Brain 2012 135 3 693 708 2-s2.0-84857617138 10.1093/brain/awr355
26. Al-Sarraj S., King A., Troakes C., Smith B., Maekawa S., Bodi I., Rogelj B., Al-Chalabi A., Hortobágyi T., Shaw C. E., p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72 -linked FTLD and MND/ALS. Acta Neuropathologica 2011 122 6 691 702 2-s2.0-82355180826 10.1007/s00401-011-0911-2
27. Cruts M., Gijselinck I., van Langenhove T., van der Zee J., van Broeckhoven C., Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends in Neurosciences 2013 36 8 450 459
28. Morris H. R., Waite A. J., Williams N. M., Neal J. W., Blake D. J., Recent advances in the genetics of the ALS-FTLD complex. Current Neurology and Neuroscience Reports 2012 12 243 250 2-s2.0-84859050052 10.1007/s11910-012-0268- 5
29. Mackenzie I. R. A., Rademakers R., Neumann M., TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet Neurology 2010 9 10 995 1007 2-s2.0-77956850818 10.1016/S1474-4422(10)70195-2
30. Vance C., Rogelj B., Hortobágyi T., De Vos K. J., Nishimura A. L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K. L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P. N., Blair I. P., Nicholson G., De Belleroche J., Gallo J.-M., Miller C. C., Shaw C. E., Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 323 5918 1208 1211 2-s2.0-61349162349 10.1126/science. 1165942
31. Andersen P. M., Al-Chalabi A., Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nature Reviews Neurology 2011 7 11 603 615 2-s2.0-80755133370 10.1038/nrneurol.2011.150
32. Deng H.-X., Chen W., Hong S.-T., Boycott K. M., Gorrie G. H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., Jiang H., Hirano M., Rampersaud E., Jansen G. H., Donkervoort S., Bigio E. H., Brooks B. R., Ajroud K., Sufit R. L., Haines J. L., Mugnaini E., Pericak-Vance M. A., Siddique T., Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011 477 7363 211 215 2-s2.0-80052580969 10.1038/nature10353
33. Synofzik M., Maetzler W., Grehl T., Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiology of Aging 2012 33 12 13 17
34. Kwiatkowski T. J. Jr., Bosco D. A., LeClerc A. L., Tamrazian E., Vanderburg C. R., Russ C., Davis A., Gilchrist J., Kasarskis E. J., Munsat T., Valdmanis P., Rouleau G. A., Hosler B. A., Cortelli P., De Jong P. J., Yoshinaga Y., Haines J. L., Pericak-Vance M. A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P. C., Horvitz H. R., Landers J. E., Brown R. H. Jr., Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009 323 5918 1205 1208 2-s2.0-61349156118 10.1126/science.1166066
35. Rademakers R., Stewart H., DeJesus-Hernandez M., Krieger C., Graff-Radford N., Fabros M., Briemberg H., Cashman N., Eisen A., Mackenzie I. R. A., FUS gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle and Nerve 2010 42 2 170 176 2-s2.0-77955127561 10.1002/mus.21665
36. Mackenzie I. R. A., Bigio E. H., Ince P. G., Geser F., Neumann M., Cairns N. J., Kwong L. K., Forman M. S., Ravits J., Stewart H., Eisen A., McClusky L., Kretzschmar H. A., Monoranu C. M., Highley J. R., Kirby J., Siddique T., Shaw P. J., Lee V. M.-Y., Trojanowski J. Q., Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology 2007 61 5 427 434 2-s2.0-34249946466 10.1002/ana.21147 (Pubitemid 46878770)
37. Tan C.-F., Eguchi H., Tagawa A., Onodera O., Iwasaki T., Tsujino A., Nishizawa M., Kakita A., Takahashi H., TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathologica 2007 113 5 535 542 2-s2.0-34247606414 10.1007/s00401-007-0206-9 (Pubitemid 46672599)
38. Sreedharan J., Blair I. P., Tripathi V. B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J. C., Williams K. L., Buratti E., Baralle F., De Belleroche J., Mitchell J. D., Leigh P. N., Al-Chalabi A., Miller C. C., Nicholson G., Shaw C. E., TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008 319 5870 1668 1672 2-s2.0-41149180753 10.1126/science.1154584 (Pubitemid 351432505)
39. Dickson D. W., Kouri N., Murray M. E., Josephs K. A., Neuropathology of frontotemporal lobar degeneration-Tau (FTLD-Tau). Journal of Molecular Neuroscience 2011 45 3 384 389 2-s2.0-80855138704 10.1007/s12031-011-9589-0
40. Munoz D. G., Ros R., Fatas M., Bermejo F., de Yebenes J. G., Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. American Journal of Alzheimer's Disease and other Dementias 2007 22 4 294 299 2-s2.0-34548288059 10.1177/1533317507302320 (Pubitemid 47330149)
41. Sieben A., van Langenhove T., Engelborghs S., The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathologica 2012 124 3 353 372 10.1007/s00401-012-1029-x
42. Cairns N. J., Neumann M., Bigio E. H., Holm I. E., Troost D., Hatanpaa K. J., Foong C., White C. L. III, Schneider J. A., Kretzschmar H. A., Carter D., Taylor-Reinwald L., Paulsmeyer K., Strider J., Gitcho M., Goate A. M., Morris J. C., Mishra M., Kwong L. K., Stieber A., Xu Y., Forman M. S., Trojanowski J. Q., Lee V. M.-Y., Mackenzie I. R. A., TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. The American Journal of Pathology 2007 171 1 227 240 2-s2.0-34547663747 10.2353/ajpath.2007. 070182 (Pubitemid 47342406)
43. Gass J., Cannon A., Mackenzie I. R., Boeve B., Baker M., Adamson J., Crook R., Melquist S., Kuntz K., Petersen R., Josephs K., Pickering-Brown S. M., Graff-Radford N., Uitti R., Dickson D., Wszolek Z., Gonzalez J., Beach T. G., Bigio E., Johnson N., Weintraub S., Mesulam M., White C. L. III, Woodruff B., Caselli R., Hsiung G.-Y., Feldman H., Knopman D., Hutton M., Rademakers R., Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics 2006 15 20 2988 3001 2-s2.0-33749568019 10.1093/hmg/ddl241 (Pubitemid 44530703)
44. Josephs K. A., Stroh A., Dugger B., Dickson D. W., Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathologica 2009 118 3 349 358 2-s2.0-68349088087 10.1007/s00401-009-0547-7
45. Levine T. P., Daniels R. D., Gatta A. T., Wong L. H., Hayes M. J., The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013 29 499 503
46. Ciura S., Lattante S., le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E., Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Annals of Neurology 2013 74 2 180 187 10.1002/ana.23946
47. 2 repeat in ALS with a C9orf72 expansion. The American Journal of Human Genetics 2013 92 981 989
48. Todd P. K., Paulson H. L., RNA-mediated neurodegeneration in repeat expansion disorders. Annals of Neurology 2010 67 3 291 300 2-s2.0-77950529265 10.1002/ana.21948
49. Miller J. W., Urbinati C. R., Teng-Umnuay P., Stenberg M. G., Byrne B. J., Thornton C. A., Swanson M. S., Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. The EMBO Journal 2000 19 17 4439 4448 2-s2.0-0034282958
50. Sofola O. A., Jin P., Qin Y., Duan R., Liu H., de Haro M., Nelson D. L., Botas J., RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007 55 4 565 571 2-s2.0-34547697173 10.1016/j.neuron.2007.07.021 (Pubitemid 47223640)
51. Timchenko L. T., Miller J. W., Timchenko N. A., Devore D. R., Datar K. V., Lin L., Roberts R., Thomas Caskey C., Swanson M. S., Identification of a (CUG)(n) triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Research 1996 24 22 4407 4414 2-s2.0-0029919450 10.1093/nar/24.22.4407 (Pubitemid 26388627)
52. White M. C., Gao R., Xu W., Mandal S. M., Lim J. G., Hazra T. K., Wakamiya M., Edwards S. F., Raskin S., Teive H. A. G., Zoghbi H. Y., Sarkar P. S., Ashizawa T., Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genetics 2010 6 6 e1000984 2-s2.0-77957086635 10.1371/journal.pgen.1000984
53. Ash P. E., Bieniek K. F., Gendron T. F., Unconventional translation of C9orf72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013 77 4 639 646
54. Mori K., Weng S. M., Arzberger T., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013 339 6125 1335 1338 10.1126/science.1232927
55. Miller R. G., Mitchell J. D., Moore D. H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2012 3 CD001447
56. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M. L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modugno N., Siciliano G., Isidoro C., Murri L., Ruggieri S., Paparelli A., Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 6 2052 2057 2-s2.0-41149124406 10.1073/pnas.0708022105 (Pubitemid 351439463)
57. Gordon P. H., Moore D. H., Miller R. G., Florence J. M., Verheijde J. L., Doorish C., Hilton J. F., Spitalny G. M., MacArthur R. B., Mitsumoto H., Neville H. E., Boylan K., Mozaffar T., Belsh J. M., Ravits J., Bedlack R. S., Graves M. C., McCluskey L. F., Barohn R. J., Tandan R., Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology 2007 6 12 1045 1053 2-s2.0-36148960127 10.1016/S1474- 4422(07)70270-3 (Pubitemid 350116691)
58. Kiernan M. C., Vucic S., Cheah B. C., Turner M. R., Eisen A., Hardiman O., Burrell J. R., Zoing M. C., Amyotrophic lateral sclerosis. The Lancet 2011 377 9769 942 955 2-s2.0-79952486262 10.1016/S0140-6736(10)61156-7
59. Orrell R. W., Lane R. J., Ross M., Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2007 1 CD002829 2-s2.0-34247873012
60. Boxer A. L., Gold M., Huey E., The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimer's & Dementia 2013 9 2 189 198 10.1016/j.jalz.2012.03.003
61. Hu B., Ross L., Neuhaus J., Knopman D., Kramer J., Boeve B., Caselli R. J., Graff-Radford N., Mendez M. F., Miller B. L., Boxer A. L., Off-label medication use in frontotemporal dementia. American Journal of Alzheimer's Disease and other Dementias 2010 25 2 128 133 2-s2.0-77749270419 10.1177/1533317509356692
62. Huey E. D., Putnam K. T., Grafman J., A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006 66 1 17 22 2-s2.0-33645814682 10.1212/01.wnl.0000191304.55196.4d (Pubitemid 43739585)
63. Southwell A. L., Skotte N. H., Bennett C. F., Hayden M. R., Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine 2012 18 634 643
64. Bennett C. F., Swayze E. E., RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology 2010 50 259 293 2-s2.0-77949512140 10.1146/annurev.pharmtox.010909.105654
65. Crooke S. T., Molecular mechanisms of action of antisense drugs. Biochimica et Biophysica Acta 1999 1489 1 31 43 2-s2.0-0032700656 10.1016/S0167-4781(99)00148-7
66. Cerritelli S. M., Crouch R. J., Ribonuclease H: the enzymes in eukaryotes. The FEBS Journal 2009 276 6 1494 1505 2-s2.0-61349102407 10.1111/j.1742-4658.2009.06908.x
67. Dias N., Stein C. A., Antisense oligonucleotides: basic concepts and mechanisms. Molecular Cancer Therapeutics 2002 1 5 347 355 2-s2.0-0000015743
68. Aoki Y., Nakamura A., Yokota T., Saito T., Okazawa H., Nagata T., Takeda S., In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Molecular Therapy 2010 18 11 1995 2005 2-s2.0-78049472917 10.1038/mt.2010.186
69. Aoki Y., Yokota T., Nagata T., Nakamura A., Tanihata J., Saito T., Takeda S., Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America 2012 109 13763 13768
70. Aoki Y., Nagata T., Yokota T., Nakamura A., Wood M. J., Partridge T., Takeda S., Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin α 2 chain-null congenital muscular dystrophy mice. Human Molecular Genetics 2013 10.1093/hmg/ddt341
71. Aoki Y., Yokota T., Wood M. J., Development of multiexon skipping antisense oligonucleotide therapy for duchenne muscular dystrophy. Biomedical Research International 2013 2013 8 10.1155/2013/402369 402369
72. Summerton J., Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochimica et Biophysica Acta 1999 1489 1 141 158 2-s2.0-0032699477 10.1016/S0167-4781(99)00150-5
73. Prakash T. P., An overview of sugar-modified oligonucleotides for antisense therapeutics. Chemistry and Biodiversity 2011 8 9 1616 1641 2-s2.0-80052913097 10.1002/cbdv.201100081
74. Kumar R., Singh S. K., Koshkin A. A., Rajwanshi V. K., Meldgaard M., Wengel J., The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2′-thio-LNA. Bioorganic and Medicinal Chemistry Letters 1998 8 16 2219 2222 2-s2.0-0032544134 10.1016/S0960-894X(98)00366-7 (Pubitemid 28561609)
75. Kauppinen S., Vester B., Wengel J., Locked nucleic acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics. Drug Discovery Today: Technologies 2005 2 3 279 282 2-s2.0-27244447208 10.1016/j.ddtec.2005.08. 012
76. Petersen M., Wengel J., LNA: a versatile tool for therapeutics and genomics. Trends in Biotechnology 2003 21 2 74 81 2-s2.0-0037310844 10.1016/S0167-7799(02)00038-0 (Pubitemid 36165007)
77. Goemans N. M., Tulinius M., van den Akker J. T., Burm B. E., Ekhart P. F., Heuvelmans N., Holling T., Janson A. A., Platenburg G. J., Sipkens J. A., Sitsen J. M. A., Aartsma-Rus A., Van Ommen G.-J. B., Buyse G., Darin N., Verschuuren J. J., Campion G. V., Kimpe S. J. D., Van Deutekom J. C., Systemic administration of PRO051 in Duchenne's muscular dystrophy. The New England Journal of Medicine 2011 364 16 1513 1522 2-s2.0-79955158683 10.1056/NEJMoa1011367
78. Banks W. A., Farr S. A., Butt W., Kumar V. B., Franko M. W., Morley J. E., Delivery across the blood-brain barrier of antisense directed against amyloid β: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. Journal of Pharmacology and Experimental Therapeutics 2001 297 3 1113 1121 2-s2.0-0035015218 (Pubitemid 32472511)
79. Erickson M. A., Niehoff M. L., Farr S. A., Morley J. E., Dillman L. A., Lynch K. M., Banks W. A., Peripheral administration of antisense oligonucleotides targeting the amyloid- β protein precursor reverses A β PP and LRP-1 overexpression in the aged SAMP8 mouse brain. Journal of Alzheimer's Disease 2012 28 4 951 960 2-s2.0-84858020530 10.3233/JAD-2011-111517
80. Kordasiewicz H. B., Stanek L. M., Wancewicz E. V., Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012 74 1031 1044
81. Smith R. A., Miller T. M., Yamanaka K., Monia B. P., Condon T. P., Hung G., Lobsiger C. S., Ward C. M., McAlonis-Downes M., Wei H., Wancewicz E. V., Bennett C. F., Cleveland D. W., Antisense oligonucleotide therapy for neurodegenerative disease. The Journal of Clinical Investigation 2006 116 8 2290 2296 2-s2.0-33746667851 10.1172/JCI25424 (Pubitemid 44162339)
82. Benoist M., Boulu P., Hayem G., Epidural steroid injections in the management of low-back pain with radiculopathy: an update of their efficacy and safety. European Spine Journal 2012 21 204 213 2-s2.0-80052668333 10.1007/s00586-011-2007-z
83. Freise H., van Aken H. K., Risks and benefits of thoracic epidural anaesthesia. British Journal of Anaesthesia 2011 107 6 859 868 2-s2.0-81855173502 10.1093/bja/aer339
84. Hayek S. M., Deer T. R., Pope J. E., Panchal S. J., Patel V., Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011 14 3 219 248 2-s2.0-79957804553
85. Fishman R. A., Cerebrospinal Fluid in Diseases of the Nervous System 1992 Philadelphia, Pa, USA Saunders
86. Dash A. K., Cudworth G. C. II, Therapeutic applications of implantable drug delivery systems. Journal of Pharmacological and Toxicological Methods 1998 40 1 1 12 2-s2.0-0032408601 10.1016/S1056-8719(98)00027-6 (Pubitemid 29062900)
87. North R. B., Levy R. M., Neurosurgical Management of Pain 1997 New York, NY, USA Springer
88. Miller T. M., Pestronk A., David W., An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. The Lancet Neurology 2013 12 5 435 442
89. Armakola M., Higgins M. J., Figlry M. D., Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nature Genetics 2012 44 12 1302 1309 10.1038/ng.2434
90. Kremer B., Goldberg P., Andrew S. E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E., Bird T. D., Hayden M. R., A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. The New England Journal of Medicine 1994 330 20 1401 1406 2-s2.0-0028316870 10.1056/NEJM199405193302001 (Pubitemid 24139231)
91. Sobczak K., de Mezer M., Michlewski G., Krol J., Krzyzosiak W. J., RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Research 2003 31 19 5469 5482 2-s2.0-0142009656 10.1093/nar/gkg766 (Pubitemid 37441917)
92. Hu J., Matsui M., Gagnon K. T., Schwartz J. C., Gabillet S., Arar K., Wu J., Bezprozvanny I., Corey D. R., Inhibiting expression of mutant Huntingtin and Ataxin-3 by targeting expanded CAG repeat RNAs. Nature Biotechnology 2009 27 5 478 484 2-s2.0-66149181896 10.1038/nbt.1539
93. Nasir J., Floresco S. B., O'Kusky J. R., Diewert V. M., Richman J. M., Zeisler J., Borowski A., Marth J. D., Phillips A. G., Hayden M. R., Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995 81 5 811 823 2-s2.0-0029055717
94. White J. K., Auerbach W., Duyao M. P., Vonsattel J.-P., Gusella J. F., Joyner A. L., MacDonald M. E., Huntington is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nature Genetics 1997 17 4 404 410 2-s2.0-0030613177 (Pubitemid 27518388)
95. Burnett B., Li F., Pittman R. N., The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Human Molecular Genetics 2003 12 23 3195 3205 2-s2.0-0345099501 10.1093/hmg/ddg344 (Pubitemid 37508890)
96. Evers M. M., Pepers B. A., van Deutekom J. C. T., Mulders S. A. M., den Dunnen J. T., Aartsma-Rus A., van Ommen G.-J. B., van Roon-Mom W. M. C., Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE 2011 6 9 2-s2.0-80052383976 10.1371/journal.pone.0024308 e24308
97. Evers M. M., Tran H. D., Zalachoras I., Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiology of Disease 2013 58 49 56 10.1016/j.nbd.2013.04.019
98. Brook J. D., McCurrach M. E., Harley H. G., Buckler A. J., Church D., Aburatani H., Hunter K., Stanton V. P., Thirion J.-P., Hudson T., Sohn R., Zemelman B., Snell R. G., Rundle S. A., Crow S., Davies J., Shelbourne P., Buxton J., Jones C., Juvonen V., Johnson K., Harper P. S., Shaw D. J., Housman D. E., Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992 68 4 799 808 2-s2.0-0026566108
99. Mahadevan M., Tsilfidis C., Sabourin L., Shutler G., Amemiya C., Jansen G., Neville C., Narang M., Barcelo J., O'Hoy K., Leblond S., Earle-MacDonald J., De Jong P. J., Wieringa B., Korneluk R. G., Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992 255 5049 1253 1255 2-s2.0-0026603841
100. Taneja K. L., McCurrach M., Schalling M., Housman D., Singer R. H., Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. The Journal of Cell Biology 1995 128 6 995 1002 2-s2.0-0028947317 10.1083/jcb.128.6.995
101. Davis B. M., Mccurrach M. E., Taneja K. L., Singer R. H., Housman D. E., Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proceedings of the National Academy of Sciences of the United States of America 1997 94 14 7388 7393 2-s2.0-0030841672
102. Wheeler T. M., Leger A. J., Pandey S. K., Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012 488 111 115